AAPL   325.67 (+0.72%)
MSFT   185.29 (+0.21%)
FB   230.64 (-0.89%)
AMZN   2,484.11 (+0.47%)
NVDA   351.99 (-0.29%)
CGC   16.58 (+2.73%)
BABA   218.42 (+1.91%)
MU   49.10 (+4.87%)
GE   7.33 (+3.97%)
TSLA   885.36 (+0.43%)
AMD   52.90 (-1.20%)
T   31.57 (+1.87%)
ACB   14.34 (-1.31%)
F   6.23 (+5.42%)
GILD   74.19 (+1.27%)
DIS   122.22 (+2.92%)
NFLX   424.15 (-0.74%)
BAC   26.04 (+4.83%)
BA   172.79 (+12.71%)
AAPL   325.67 (+0.72%)
MSFT   185.29 (+0.21%)
FB   230.64 (-0.89%)
AMZN   2,484.11 (+0.47%)
NVDA   351.99 (-0.29%)
CGC   16.58 (+2.73%)
BABA   218.42 (+1.91%)
MU   49.10 (+4.87%)
GE   7.33 (+3.97%)
TSLA   885.36 (+0.43%)
AMD   52.90 (-1.20%)
T   31.57 (+1.87%)
ACB   14.34 (-1.31%)
F   6.23 (+5.42%)
GILD   74.19 (+1.27%)
DIS   122.22 (+2.92%)
NFLX   424.15 (-0.74%)
BAC   26.04 (+4.83%)
BA   172.79 (+12.71%)
AAPL   325.67 (+0.72%)
MSFT   185.29 (+0.21%)
FB   230.64 (-0.89%)
AMZN   2,484.11 (+0.47%)
NVDA   351.99 (-0.29%)
CGC   16.58 (+2.73%)
BABA   218.42 (+1.91%)
MU   49.10 (+4.87%)
GE   7.33 (+3.97%)
TSLA   885.36 (+0.43%)
AMD   52.90 (-1.20%)
T   31.57 (+1.87%)
ACB   14.34 (-1.31%)
F   6.23 (+5.42%)
GILD   74.19 (+1.27%)
DIS   122.22 (+2.92%)
NFLX   424.15 (-0.74%)
BAC   26.04 (+4.83%)
BA   172.79 (+12.71%)
AAPL   325.67 (+0.72%)
MSFT   185.29 (+0.21%)
FB   230.64 (-0.89%)
AMZN   2,484.11 (+0.47%)
NVDA   351.99 (-0.29%)
CGC   16.58 (+2.73%)
BABA   218.42 (+1.91%)
MU   49.10 (+4.87%)
GE   7.33 (+3.97%)
TSLA   885.36 (+0.43%)
AMD   52.90 (-1.20%)
T   31.57 (+1.87%)
ACB   14.34 (-1.31%)
F   6.23 (+5.42%)
GILD   74.19 (+1.27%)
DIS   122.22 (+2.92%)
NFLX   424.15 (-0.74%)
BAC   26.04 (+4.83%)
BA   172.79 (+12.71%)
Log in

NASDAQ:ALKSAlkermes Stock Price, Forecast & News

$16.86
+0.15 (+0.90 %)
(As of 06/3/2020 03:39 PM ET)
Add
Compare
Today's Range
$16.62
Now: $16.86
$16.97
50-Day Range
$13.31
MA: $15.67
$16.86
52-Week Range
$11.98
Now: $16.86
$25.35
Volume23,585 shs
Average Volume1.30 million shs
Market Capitalization$2.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More
Alkermes logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$0.59 per share
Book Value$6.89 per share

Profitability

Net Income$-196,620,000.00

Miscellaneous

Employees2,235
Market Cap$2.68 billion
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

How has Alkermes' stock been impacted by COVID-19 (Coronavirus)?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALKS shares have increased by 3.8% and is now trading at $16.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alkermes?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Alkermes.

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, April, 29th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.07. The company had revenue of $246.20 million for the quarter, compared to the consensus estimate of $230.53 million. Alkermes had a negative net margin of 11.63% and a positive return on equity of 4.99%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.17) EPS. View Alkermes' earnings history.

What price target have analysts set for ALKS?

12 equities research analysts have issued 12 month price targets for Alkermes' stock. Their forecasts range from $16.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $21.17 in the next twelve months. This suggests a possible upside of 25.5% from the stock's current price. View analysts' price targets for Alkermes.

Has Alkermes been receiving favorable news coverage?

News coverage about ALKS stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alkermes earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAlkermes.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,290,000 shares, an increase of 16.6% from the April 15th total of 7,970,000 shares. Based on an average daily trading volume, of 2,020,000 shares, the short-interest ratio is presently 4.6 days. Approximately 5.9% of the shares of the company are short sold. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Who are Alkermes' key executives?

Alkermes' management team includes the following people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (13.82%), Primecap Management Co. CA (5.67%), BlackRock Inc. (5.55%), Sarissa Capital Management LP (4.53%), Camber Capital Management LP (3.81%) and State Street Corp (2.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View institutional ownership trends for Alkermes.

Which major investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Two Sigma Investments LP, BlackRock Inc., Deutsche Bank AG, Engineers Gate Manager LP, Rafferty Asset Management LLC, Spark Investment Management LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops. View insider buying and selling activity for Alkermes.

Which major investors are buying Alkermes stock?

ALKS stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Maverick Capital Ltd., Camber Capital Management LP, BNP Paribas Arbitrage SA, Invesco Ltd., Atom Investors LP, UBS Group AG, and Krensavage Asset Management LLC. View insider buying and selling activity for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $16.86.

How big of a company is Alkermes?

Alkermes has a market capitalization of $2.68 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.